Trial Profile
Remission Through Early Monitored Insulin Therapy - Duration Month
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REMIT-DM
- 08 Oct 2020 Status changed from active, no longer recruiting to completed.
- 16 Dec 2019 Planned End Date changed from 1 Jun 2020 to 30 Oct 2020.
- 16 Dec 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Oct 2020.